 My first meeting was in 1992 and the memory is at the end, it's difficult to understand the step procedure and I feel never to understand it at that moment. I have read it about it but when I was there I do not understand what's happening exactly. Other points were the discussion of the risk analysis principles for the CCPR and before we had even problems with the EU and we had some new steps introduced, 7ABC, so somewhere in time they were skipped and we go over to the system we have now, the EU say reservation and the SHARP man said step 5A or in few cases step 4. For the coming year it's what we are discussing now under agenda item 13, how to come forward with the review of the old active substances and in parallel all the new active substances. I think that will be a huge amount of work not only for the JMP but also the CCPR has to think a little bit about maybe structure and so on. My understanding is that we need to be more strict with the procedural manual at the end so if there is no commitment by an observer or a data sponsor then to say okay now it's end of this substance so to ask again and again we can do it until 25 years but then we should say no. Not to worry about the step procedure when they do not understand it with the first meeting. That's something I think it's a good system but to understand it from my point of view you need one cycle of steps to really understand when what happens. This system is very good for all those developing countries not having all the data available so that they could trade their products even when you sometimes said reservations. But we take over all those MLs where we do not have reservation. That's for sure because it's legal right in European legislation.